| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2872176 | The Annals of Thoracic Surgery | 2015 | 6 Pages |
Abstract
Five-year survival after SLTx for emphysema was comparable to that for BLTx in cohorts from our institution and from the UNOS national database. Further study should focus on the mechanism behind these improved outcomes. Given the potential for a larger number of life-years saved, SLTx should continue to be considered a therapeutic option in appropriately selected patients with chronic obstructive pulmonary disease (COPD).
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Daine T. MD, Martin MD, T. Brett MD, John D. MD, Joseph C. MD, Frederick L. MD, Ashok N. MD, Robert A. MD, MPH, David A. MD, Michael J. MD,